The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts hydrates solvates polymorphs thereof. In particular it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof including without limitation subjects having or at risk for age related cognitive impairment Mild Cognitive Impairment (MCI) dementia Alzheimer s Disease(AD) prodromal AD post traumatic stress disorder (PTSD) schizophrenia amyotrophic lateral sclerosis (ALS) and cancer therapy related cognitive impairment.
